A total of 196 patients with MM were included in the study—of these patients, 114 had MM with co-existing type II diabetes and/or dyslipidemia and received IMiDs but not a PPAR agonist during the course of their anti-myeloma treatment (they received other diabetes medications, such as metformin or insulin, and/or statins for dyslipidemia); 82 patients had MM with co-existing type II diabetes and/or dyslipidemia and received a PPAR agonist concurrently with an IMiD-containing therapy for MM management. The gene discussed is PPARA; the disease is metabolic syndrome.